Trial reportClinical and experimental medicine2026
A prospective, open, single-arm clinical trial of fludarabine- cyclophosphamide-porcine anti-lymphocyte globulin conditioning combined with matched sibling donor hematopoietic stem cell transplantation in the treatment of severe aplastic anemia.
Trial report in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hematopoietic stem cell transplantation (HSCT) remains an effective treatment for severe aplastic anemia (SAA), but the optimal conditioning regimen has yet to be established. This study aimed to evaluate the safety and efficacy of a conditioning regimen consisting of fludarabine (Flu), cyclophosphamide (Cy), and porcine anti-lymphocyte globulin (p-ATG). This prospective single-arm clinical trial enrolled 48 SAA patients who underwent HLA-matched sibling transplantation. The conditioning regimen consisted of p-ATG (120 mg/kg), Cy (120 mg/kg), and Flu (120 mg/m²). All patients achieved neutrophil engraftment (median time of 12 days), with 98% attaining platelet recovery (median time of 13 days). Complete donor chimerism was achieved in 95.8% of patients by day + 30. Cardiac toxicity was observed in three patients. No grade 4 regimen-related toxicity was observed. The cumulative incidences of grade acute GVHD and chronic GVHD were 21.0% (95% CI: 8.5% to 31.8%) and 15.8% (95% CI: 4.2% to 25.9%), respectively. The 1-year overall survival rate was 97.9% (95% CI: 94% to 100%). In this single-arm study, these results indicate that the conditioning regimen of p-ATG combined with Flu and Cy is associated with stable engraftment, an acceptable safety profile, and a manageable incidence of GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.